Effect of Carboxymesteine Oral Solution Combined with Recombinant Human Interferon α1b in the Treatment of Acute Asthmatic Bronchitis in Children
Objective To analyze the therapeutic effects of recombinant human interferon α1b monotherapy and combined carboxymesteine oral solution in children with acute asthmatic bronchitis.Methods The data of 100 children with acute asthmatic bronchitis in hospital from June 2021 to June 2023 were retrospectively analyzed and divided into control group and observation group with 50 cases in each group according to different treatment plans.The control group was treated with recombinant human interferon α1b,and the observation group was treated with carboxymesteine oral solution plus recombinant human interferon α1b.The clinical efficacy,duration of major symptom remission,airway inflammation related factors[chemokine 3(CCL3),high mobility group protein B1(HMGB1),α1-acidic glycoprotein(α1-AG)],T lymphocytes(CD3+,CD4+,CD4+/CD8+)and adverse reactions were compared between the two groups.Results The total effective rate of observation group was higher than that of control group(P＜0.05).After treatment,the relief time of symptoms such as shortness of breath,wheezing,cough and pulmonary rales was reduced in the observation group(P＜0.05).After 4 and 7 days of treatment,CCL3,HMGB1 and α1-AG in both groups were significantly decreased compared with before treatment,and the observation group was lower than the control group(P＜0.05).After 4 and 7 days of treatment,CD3+,CD4+and CD4+/CD8+in both groups were significantly higher than before treatment,and the observation group was higher than the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Carboxymesteine oral solution combined with recombinant human interferon α1b in the treatment of acute asthmatic bronchitis can inhibit airway inflammation,regulate body immunity,accelerate symptom relief,with significant efficacy and high safety.
acute asthmatic bronchitiscarboxymesteine oral solutionrecombinant human interferon α1bt lymphocyteschemokine 3high mobility group protein b1alpha 1-acidic glycoprotein
万方数据
维普
